Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background A large proportion of colorectal cancer patients does not benefit from the use of anti-epidermal growth factor receptor (EGFR) treatment although in the absence of a mutation of the K-RAS gene. Preliminary observations suggested that HER-3, insulin-like growth factor-1 (IGF-1), nuclear factor-kB (NF-kB) and EGFR gene copy number (GCN) might identify patients not likely to benefit from anti-EGFR therapy. We tested the interaction between HER-3, IGF-1, NF-kB, EGFR GCN and K-RAS mutational analysis to verify the relative ability of these variables to identify a subgroup of patients more likely to benefit from EGFR-targeted treatment among those harbouring a K-RAS wild-type status.Patients and methods We retrospectively collected tumours from 168 patients with metastatic colorectal cancer treated with irinotecan-cetuximab. K-RAS was assessed with direct sequencing, EGFR amplification was assessed by chromogenic in situ hybridisation (CISH) and HER-3, IGF-1 and NF-kB were assessed by immunohistochemistry.Results In patients with K-RAS wild-type tumours, the following molecular factors resulted independently associated with response rate: HER-3 [odds ratio (OR)=4.6, 95% confidence interval (CI) 1.8-13.6, P=0.02], IGF-1 (OR=4.2, 95% CI 2-10.2, P=0.003) and EGFR GCN (OR=4.1, 95% CI 1.9-26.2, P=0.04). These factors also independently correlated with overall survival as follows: HER-3 [hazard ratio (HR)=0.4, 95% CI 0.28-0.85, P=0.008], IGF-1 (HR=0.47, 95% CI 0.24-0.76, P<0.0001) and EGFR GCN (HR=0.59, 95% CI 0.22-0.89, P=0.04).Discussion We believe that our data may help further composing the molecular mosaic of EGFR-resistant tumours. The role of HER-3, IGF-1 and CISH EGFR GCN should be prospectively validated in clinical trials investigating anti-EGFR treatment strategies in colorectal cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Extensive data suggest that aberrant HER3 in mCRC may also reduce the efficacy of anti-EGFR therapy [172,182].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [172]
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [172]
In the citing paper
“Multiple clinical studies have demonstrated that IGF1-negative patients with CRC in KRAS-WT treated with irinotecan-cetuximab have higher responses, higher median-PFS and higher median-OS than IGF1-positive patients [172,175].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [172]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“K-RAS wild type) [1–3].”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 5×
“On the contrary, a retrospective consortium analysis suggested that objective response rates in K-RAS wild-type patients receiving cetuximab could be improved by additional genotyping of b-RAF, NRAS and PIK3CA [10].”
BackgroundInfluentialWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“For example, preliminary data about the role of b-RAF mutational status seemed initially promising for a straightforward application in the clinical practice, but a large subsequent analysis from the CRYSTAL trial demonstrated that b-RAF although possessing a possible prognostic role had no predictive value [4–9].”
ResultLièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734 · cited 1×
“K-RAS wild type) [1–3].”
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673 · cited 1×
“A further comprehensive analysis of b-RAF, EGFR amplification and PTEN expression reached similar conclusions [11].”
ResultMechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550 · cited 1×
“Preclinical data about growth factors receptors interdependence strongly suggested that human epidermal growth factor receptor-3 (HER-3) and the insulinlike growth factor-1 (IGF-1) may interfere with biological activity of the EGFR respectively through EGFR lateral signalling and IGF-1-driven phosphoinositide 3-Akt ov…”
BackgroundLoupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403 · cited 1×
“For example, preliminary data about the role of b-RAF mutational status seemed initially promising for a straightforward application in the clinical practice, but a large subsequent analysis from the CRYSTAL trial demonstrated that b-RAF although possessing a possible prognostic role had no predictive value [4–9].”
ResultSelf-citationChromogenic in Situ Hybridization
Tanner, M., Gancberg, D., Di Leo, A., Larsimont, D., Rouas, G., Piccart, M. J., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64785-2 · Cited by 383
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5956 · Cited by 333 · cited 1×
“Several studies addressed EGFR GCN as a predictive factor for anti-EGFR therapy [36–38].”
BackgroundSelf-citationCappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm492 · Cited by 267 · cited 1×
“Several studies addressed EGFR GCN as a predictive factor for anti-EGFR therapy [36–38].”
BackgroundExpression of insulin-like growth factor-1 receptor in human colorectal cancer
Hakam, A., Yeatman, T. J., Lu, L., Mora, L., Marcet, G., Nicosia, S. V., Karl, R. C., & Coppola, D. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90027-8 · Cited by 239 · cited 1×
“previously reported [25–27].”
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B., Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-38 · Cited by 239
ErbB-3 Predicts Survival in Ovarian Cancer
Tanner, B., Hasenclever, D., Stern, K., Schormann, W., Bezler, M., Hermes, M., Brulport, M., Bauer, A., Schiffer, I. B., Gebhard, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8397 · Cited by 231
Expression of the c-erbB-3 protein in normal human adult and fetal tissues.
Prigent, S. A., Lemoine, N. R., Hughes, C., Plowman, G. D., Selden, C., & Gullick, W. (1992) · PubMed · Cited by 182
Shia, J., Klimstra, D. S., Li, A. R., Qin, J., Saltz, L., Teruya-Feldstein, J., Akram, M., Chung, K. Y., Yao, D., Paty, P. B., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800417 · Cited by 163 · cited 1×
“previously described [28–33].”
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon
Freier, S., Weiss, O., Eran, M., Flyvbjerg, A., Dahan, R., Nephesh, I., Safra, T., Shiloni, E., & Raz, I. (1999) · Gut · doi:10.1136/gut.44.5.704 · Cited by 150 · cited 1×
“previously reported [25–27].”
Buck, E. A., Eyzaguirre, A., Haley, J. D., Gibson, N. W., Cagnoni, P. J., & Iwata, K. K. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0007 · Cited by 133 · cited 1×
“Preclinical data about growth factors receptors interdependence strongly suggested that human epidermal growth factor receptor-3 (HER-3) and the insulinlike growth factor-1 (IGF-1) may interfere with biological activity of the EGFR respectively through EGFR lateral signalling and IGF-1-driven phosphoinositide 3-Akt ov…”
BackgroundGrowth factor receptor interplay and resistance in cancer
Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D., & Nicholson, R. I. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01275 · Cited by 130 · cited 1×
“Preclinical data about growth factors receptors interdependence strongly suggested that human epidermal growth factor receptor-3 (HER-3) and the insulinlike growth factor-1 (IGF-1) may interfere with biological activity of the EGFR respectively through EGFR lateral signalling and IGF-1-driven phosphoinositide 3-Akt ov…”
BackgroundScartozzi, M., Bearzi, I., Pierantoni, C., Mandolesi, A., Loupakis, F., Zaniboni, A., Catalano, V., Quadri, A., Zorzi, F., Berardi, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5022 · Cited by 125 · cited 3×
“In fact, NF-kB overexpression was clinically associated with resistance to antiEGFR therapy in a study investigating 76 colorectal cancer patients treated with cetuximab [22].”
BackgroundMethodResultInfluentialSelf-citationHanna, W. M., & Kwok, K. (2006) · Modern Pathology · doi:10.1038/modpathol.3800555 · Cited by 119
Robbesom, A. A., Versteeg, E. M. M., Veerkamp, J. H., van Krieken, J. H., Bulten, H., Smits, H. T. J., Willems, L., van Herwaarden, C., Dekhuijzen, P. N. R., & Kuppevelt, T. H. V. (2003) · Modern Pathology · doi:10.1097/01.mp.0000043519.29370.c2 · Cited by 98
Frolov, A., Schuller, K., Tzeng, C.-W. D., Cannon, E. E., Ku, B. C., Howard, J. H., Vickers, S. M., Heslin, M. J., Buchsbaum, D. J., & Arnoletti, J. P. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.4.3849 · Cited by 90 · cited 1×
“Preclinical data about growth factors receptors interdependence strongly suggested that human epidermal growth factor receptor-3 (HER-3) and the insulinlike growth factor-1 (IGF-1) may interfere with biological activity of the EGFR respectively through EGFR lateral signalling and IGF-1-driven phosphoinositide 3-Akt ov…”
BackgroundBokemeyer, C., Köhne, C. H., Rougier, P. R., Stroh, C., Schlichting, M., & Cutsem, E. V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3506 · Cited by 85
Hu, Y. P., Patil, S. B., Panasiewicz, M., Li, W., Hauser, J., Humphrey, L. E., & Brattain, M. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0280 · Cited by 75
Scartozzi, M., Mandolesi, A., Giampieri, R., Pierantoni, C., Loupakis, F., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25193 · Cited by 74 · cited 1×
“Accordingly, we clinically demonstrated that HER-3 and IGF-1 may both represent predictive factors for anti-EGFR therapy in colorectal cancer patient treated with cetuximab [19, 20].”
BackgroundSelf-citationScartozzi, M., Bearzi, I., Mandolesi, A., Pierantoni, C., Loupakis, F., Zaniboni, A., Negri, F., Quadri, A., Zorzi, F., Galizia, E., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-303 · Cited by 72 · cited 1×
“previously described [28–33].”
Self-citationJain, A., Penuel, E., Mink, S., Schmidt, J., Hodge, A., Favero, K., Tindell, C., & Agus, D. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3326 · Cited by 66 · cited 1×
“Preclinical data about growth factors receptors interdependence strongly suggested that human epidermal growth factor receptor-3 (HER-3) and the insulinlike growth factor-1 (IGF-1) may interfere with biological activity of the EGFR respectively through EGFR lateral signalling and IGF-1-driven phosphoinositide 3-Akt ov…”
BackgroundScartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0119 · Cited by 63 · cited 1×
“Accordingly, we clinically demonstrated that HER-3 and IGF-1 may both represent predictive factors for anti-EGFR therapy in colorectal cancer patient treated with cetuximab [19, 20].”
BackgroundSelf-citationSclabas, G. M., Fujioka, S., Schmidt, C., Fan, Z., Evans, D. B., & Chiao, P. J. (2003) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00088-4 · Cited by 56 · cited 1×
“On the side of the EGFR-driven downstream signalling pathway along with other ‘overanalysed’ biological factors, the nuclear factor-kB (NF-kB) also showed a potential role in interfering with clinical activity of anti-EGFR monoclonal antibodies in colorectal cancer [21].”
BackgroundSholl, L. M., Iafrate, A. J., Chou, Y.-P., Wu, M., Goan, Y., Su, L., Huang, Y., Christiani, D. C., & Chirieac, L. R. (2007) · Modern Pathology · doi:10.1038/modpathol.3800946 · Cited by 49
Winder, T., Zhang, W., Yang, D., Ning, Y., Bohanes, P., Gerger, A., Wilson, P. M., Pohl, A., Mauro, D. J., Langer, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2092 · Cited by 46 · cited 1×
“In accordance to our findings, a recent study suggested that IGF-1 pathway polymorphisms are relevant molecular markers for cetuximab efficacy in wild-type K-RAS colorectal patients [35].”
ResultXu, J., Han, Y., Duan, H. Q., Gao, E., Zhang, Y., Liu, X., Zhang, J. S., Toschi, L., Galetta, D., Azzariti, A., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0512-1 · Cited by 43
Chromogenic In Situ Hybridization in Tumor Pathology
Isola, J. J., & Tanner, M. (2004) · Humana Press eBooks · doi:10.1385/1-59259-760-2:133 · Cited by 24 · cited 1×
“previously described [28–33].”
Yang, J., Busund, L., Ow, K. T., Russell, P. J., & Crowe, P. J. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0931-y · Cited by 19 · cited 1×
“previously reported [25–27].”
Finocchiaro, G., Cappuzzo, F., Rossi, E., Toschi, L., Janne, P. A., Roncalli, M. G., Ligorio, C., Rimassa, L., Santoro, A., & Varella-Garcia, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4135 · Cited by 8
Research works printed but not linked: 1
- EVan CutsemILangGFolprechtCetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trialIn Gatrointestinal Cancers Symposium 2010 (Abstr 281)
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“In a retrospective study of 168 patients with KRAS wild-type mCRC, the expression of IGF1 was evaluated in terms of clinical outcome in patients treated with irinotecan and cetuximab [94].”
BackgroundMethodPrecision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Metadata
- Authors
- Scartozzi, M., Giampieri, R., Maccaroni, E., Mandolesi, A., Giustini, L., Silva, R., Zaniboni, A., Biscotti, T., Biagetti, S., Galizia, E., Loupakis, F., Falcone, A., Bearzi, I., & Cascinu, S.
- Affiliations
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- University of Pisa (IT)
- Corresponding author
- Scartozzi, M.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 23
- Issue
- 7
- Pages
- 1706-1712
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2098286072
- Cited by
- 43
- References
- 38
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 6 · 2012: 3
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2746 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER3, insulin-like growth factor I, nuclear factor-kappaB, epidermal growth factor receptor, gene copy number, anti-EGFR therapy, predictive biomarkers, metastatic colorectal cancer, treatment response, overall survival, EGFR amplification
- MeSH terms
- Cetuximab, Irinotecan, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, DNA Mutational Analysis, Female, Humans, Insulin-Like Growth Factor I, Liver Neoplasms, Male, Middle Aged, Proto-Oncogene Proteins, Retrospective Studies, Colorectal Neoplasms, Multivariate Analysis, Logistic Models, Proportional Hazards Models, Proto-Oncogene Proteins p21(ras), NF-kappa B, Treatment Outcome, Disease-Free Survival, Gene Dosage, ras Proteins, Receptor, ErbB-3, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.